$3.03
0.66%
Nasdaq, Apr 21, 08:17 pm CET
ISIN
US8051111016
Symbol
SVRA
Sector
Industry

Savara, Inc. Stock price

$3.01
+0.20 7.12% 1M
-0.64 17.53% 6M
-0.06 1.95% YTD
-1.95 39.31% 1Y
+1.75 138.89% 3Y
+0.54 21.86% 5Y
-30.03 90.89% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
+0.08 2.73%
ISIN
US8051111016
Symbol
SVRA
Sector
Industry

Key metrics

Market capitalization $519.63m
Enterprise Value $350.12m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 3.03
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-103.20m
Free Cash Flow (TTM) Free Cash Flow $-89.11m
Cash position $196.33m
EPS (TTM) EPS $-0.48
P/E forward negative
Short interest 11.34%
Show more

Is Savara, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Savara, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Savara, Inc. forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Savara, Inc. forecast:

Buy
88%
Hold
13%

Financial data from Savara, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.28 0.28
56% 56%
-
-0.28 -0.28
56% 56%
-
- Selling and Administrative Expenses 25 25
60% 60%
-
- Research and Development Expense 78 78
76% 76%
-
-103 -103
72% 72%
-
- Depreciation and Amortization 0.28 0.28
56% 56%
-
EBIT (Operating Income) EBIT -103 -103
72% 72%
-
Net Profit -96 -96
75% 75%
-

In millions USD.

Don't miss a Thing! We will send you all news about Savara, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Savara, Inc. Stock News

Positive
Seeking Alpha
about 4 hours ago
Savara, Inc. focuses exclusively on developing its sole therapeutic product, MOLBREEVI. Its investment thesis highlights the potential of MOLBREEVI to address unmet medical needs in autoimmune pulmonary alveolar proteinosis (aPAP). Rating justification: Strong clinical data, multiple FDA designations and a clear path to regulatory approval make Savara a compelling investment opportunity.
Neutral
Business Wire
10 days ago
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to seven new employees. On April 9, 2025, the Compensation Committee of Savara's Board of Directors granted the inducement awards to seven new employees who recently joined the Company. The inducement awards ...
Neutral
Business Wire
14 days ago
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, announced encore presentations of top-line data from the pivotal, Phase 3 IMPALA-2 clinical trial of molgramostim in aPAP will be presented at the 65th Congress of the German Society of Pneumology (DGP) in Leipzig, Germany taking place April...
More Savara, Inc. News

Company Profile

Savara, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its products include AeroVanc, Molgradex, GM-CSF, and Aironite. The company was founded on April 27, 2017 and is headquartered in Austin, TX.

Head office United States
CEO Matthew Pauls
Employees 59
Founded 1995
Website www.savarapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today